Zomedica (NYSEAMERICAN:ZOM) Releases Quarterly Earnings Results

Zomedica (NYSEAMERICAN:ZOM – Get Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, Yahoo Finance reports. Zomedica had a negative net margin of 104.92% and a negative return on equity of 6.51%.

Zomedica Stock Performance

NYSEAMERICAN ZOM opened at $0.24 on Thursday. Zomedica has a 1 year low of $0.15 and a 1 year high of $0.41. The firm has a market capitalization of $235.19 million, a price-to-earnings ratio of -12.00 and a beta of 0.98.

Hedge Funds Weigh In On Zomedica

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZOM. Money Concepts Capital Corp purchased a new position in Zomedica during the 4th quarter worth approximately $25,000. West Michigan Advisors LLC purchased a new position in Zomedica during the 1st quarter worth approximately $28,000. ExodusPoint Capital Management LP purchased a new position in Zomedica during the 2nd quarter worth approximately $38,000. Jane Street Group LLC grew its position in Zomedica by 62.9% during the 4th quarter. Jane Street Group LLC now owns 269,728 shares of the company’s stock worth $44,000 after purchasing an additional 104,143 shares in the last quarter. Finally, UBS Group AG grew its position in Zomedica by 68.6% during the 3rd quarter. UBS Group AG now owns 210,693 shares of the company’s stock worth $44,000 after purchasing an additional 85,736 shares in the last quarter. 9.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Dawson James initiated coverage on Zomedica in a report on Friday, January 6th. They issued a “buy” rating and a $6.00 price target on the stock.

About Zomedica

(Get Rating)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.